| Injection site reaction is significantly associated with use of
Betaseron ®.
86% adverse injection site reactions are reported.
Additionally, 5% of users in clinical trials developed injection
site necrosis (death of cells / tissue at the injection site).
Necrotic lesions are typically 3cm diameter (larger and smaller
areas also reported) and extend to the subcutaneous fat (fat beneath
the skin) although rarely, this extends as far as the muscle tissue.
Infrequently, this has required skin grafting.
Other injection site reactions
include:
inflammation (53%), pain
(18%), hypersensitivity (3%), edema (3%) and mass formation (2%).
|
